Background {#Sec1}
==========

Both *Plasmodium falciparum* and *Plasmodium vivax* are endemic in Vanuatu (except for the islands of Aneityum and Futuna which are malaria free) and the Solomon Islands. Malaria transmission throughout Vanuatu and the Solomon Islands occurs year round with varying degrees of seasonal intensity. In Vanuatu, transmission peaks from December to April, while in the Solomon Islands there are two transmission peaks, April to September and November to February. Over the past decade malaria incidence rates have declined, and today, both countries are intensifying malaria control country wide and progressing towards malaria elimination in targeted provinces.

The success of malaria control and elimination programs in these countries relies on effective treatment of malaria cases and asymptomatic carriers. Historically, both countries used chloroquine (CQ) for treatment of uncomplicated *P. falciparum* malaria. Chloroquine-resistance (CQR) in *P. falciparum* was first reported in the early 1980s \[[@CR1]\] and subsequent loss of CQ efficacy forced a treatment policy change in the Solomon Islands and Vanuatu \[[@CR2]\]. In 1994, the Vanuatu Ministry of Health (MOH) introduced a combination therapy of CQ and sulphadoxine-pyrimethamine (SP) for treatment of uncomplicated *P. falciparum* infection, while CQ remained the prescribed treatment for *P. vivax* infections \[[@CR2]\]. Similarly, in the Solomon Islands throughout the 1990s the combination of CQ + SP was used as second-line treatment and later from 2001 to 2007, as first-line treatment \[[@CR2]\].

In 2008--2009, following WHO recommendation, Vanuatu and the Solomon Islands introduced artemether-lumefantrine (AL) as first-line treatment for uncomplicated falciparum malaria, and AL plus primaquine for treatment of malaria caused by *P. vivax* \[[@CR3]\]. These are two of the few countries where AL is used to treat both vivax and falciparum malaria, however there was limited information on the extent of parasite resistance to CQ and SP at the time of AL implementation.

SP is one of the most extensively used anti-malarials throughout the world; the SP drug combination primarily targets dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS), critical enzymes in the folate biosynthetic pathway of the malarial parasite, thereby killing the parasite. However, parasites rapidly develop resistance to SP through single nucleotide polymorphisms (SNPs) in the genes encoding DHFR and DHPS enzymes \[[@CR4]--[@CR6]\]. Drug resistant mutations occurring mainly in five amino acid residues situated close to the active site on the *P. falciparum* DHFR (A16**V**, N51**I**, C59**R**, S108**N**/**T** and I164**L**) and in four amino acid positions (F57**I**/**L**, S58**R*,*** T61**M** and S117**T**/**N**) in *P. vivax* DHFR have been widely reported \[[@CR7]--[@CR13]\]. Combinations of these mutations correlate with varying levels of SP resistance in parasites. Mutations in *P. falciparum* DHPS (S436**A**, A437**G*,*** K540**E**, A581**G** and A613**S**/**T*)*** confer resistance to sulphadoxine \[[@CR6]\]. Analogous mutations in the *P. vivax* DHPS gene have also been determined (A383**G**, A553**G** and V585) \[[@CR14], [@CR15]\] *.*

The ability to monitor for mutations in the *P. falciparum* and *P. vivax dhfr* and *dhps* genes provides a valuable method of epidemiological surveillance of SP resistance. For instance, areas experiencing higher levels of SP pressure tend to exhibit increased prevalence of *pvdhfr* mutant alleles while those areas under little or no SP pressure are more likely to maintain the wild-type *pvdhfr* genotype \[[@CR10], [@CR11]\]. Since the introduction of SP in early 1990s, two surveys have been conducted in Guadalcanal, Solomon Islands (1995--1996 \[[@CR13]\], 2004--2005 \[[@CR16]\]) and Malo Island, Vanuatu (1996--1998 \[[@CR13]\], 2005 \[[@CR17]\]). However, due to fragmented land masses in both countries, parasite population and drug resistance profiles could be very different between different islands.

This paper describes prevalence of *P. falciparum* and *P. vivax* parasites resistant to SP in three areas of Vanuatu and Solomon Islands prior to the implementation of AL. The data and results reported here provide excellent baseline information on the status of SP resistant mutations in parasite populations prior to changes in treatment guidelines. The information also enables investigations into evolution of SP resistance in *P. falciparum* and *P. vivax* populations following a parallel change of treatment policy in areas where both *Plasmodium* species co-exist.

Methods {#Sec2}
=======

Study areas and sample collection {#Sec3}
---------------------------------

Three sets of blood samples were used in this study. Two sets were obtained from epidemiological surveys conducted (2008) during the wet seasons in Tafea Province, Vanuatu and Temotu Province, Solomon Islands, the geographic locations and information regarding the demographics of the populations surveyed and consent process have been published previously \[[@CR18]\]. In brief, a school-based, mass blood survey of children (2--12 years) was performed on Tanna Island, Tafea Province which is the most southern Province of Vanuatu. In this study speciation by PCR identified 42 samples positive for *P. falciparum* infection, 92 for *P. vivax* infection and 10 for mixed *P. falciparum/P. vivax* infections. Similarly, a village-based mass blood survey encompassing all ages was conducted on Temotu Province, the most southern Province in the Solomon Islands which is made up of five main island groups: Santa Cruz, Reef Islands, Duff Islands, Utupua Island and Vanikoro Island. In this study PCR identified 118 *P. falciparum* infections, 162 *P. vivax* infections and 39 mixed *P. falciparum/P. vivax* infections. The third set of samples was obtained from febrile patients attending Auki town clinic and Kilu'Ufi hospital, Malaita Province, Solomon Islands through collaboration with the World Health Organization (WHO) and Ministry of Health, Solomon Islands. These samples were collected as part of an artemether-lumefantrine (AL, Coartem™, Novartis) efficacy study conducted within the Solomon Islands planned and executed by the WHO and MOH Solomon Islands. Malaita Province lies approximately 9°S 161°E and is the second largest and most densely populated Province of the Solomon Islands. In this study PCR identified 68 *P. falciparum* infections, 31 *P. vivax* infections and 37 mixed *P. falciparum/P. vivax* infections. Across all study sites blood samples were collected by finger prick and a blood spot (20--30 μL) was air-dried onto filter paper (Whatman No. 3), sealed in individual plastic bags containing desiccant and stored at room temperature until further processing.

Extraction of parasite DNA {#Sec4}
--------------------------

Genomic DNA was extracted from blood samples that were *P. falciparum* or *P. vivax* positive by microscopy using QIAGEN QIAamp DNA Mini Kits and a QIAcube robot (QIAGEN, Crawley, U.K.). The manufacturer's protocol (QIAamp DNA Mini and Blood Mini Handbook 2E) was followed with the modifications that only one 5 mm circle was extracted and each sample was eluted using 100 μL of AE buffer.

Confirmation of *Plasmodium spp* {#Sec5}
--------------------------------

*Plasmodium* speciation was performed by multiplex PCRs \[[@CR19]\] (*P. falciparum, P. vivax, Plasmodium ovale* or *Plasmodium malariae*) followed by a confirmatory single species PCR, as previously described \[[@CR18], [@CR20]\].

Amplification of *dhfr*and *dhps*genes {#Sec6}
--------------------------------------

Approximately 30% of PCR confirmed *Plasmodium* positive samples were selected at random for DNA sequence analysis. These samples were being used for several different studies, we were therefore limited in the number of samples we were able to analyse. DNA fragments of the *dhfr* and *dhps* genes of *P. falciparum* and *P. vivax* encompassing sites of known mutations were amplified by nested PCR as described previously \[[@CR6], [@CR14], [@CR21], [@CR22]\]. PCR products were purified using ExoSAP-IT^R^ (USB, Cleveland, OH) to remove excess primers and nucleotides according to the manufacturer's protocol and then sequenced. Sequencing was performed using Big Dye Terminator (v.3.1) on an automated DNA sequencer, ABI 3100 system, at the QIMR Berghofer Medical Research Institute Scientific Services Analytical Facility. In cases where PCR products contained multiple bands, a single band of expected size was excised from an agarose gel and purified using a NucleoSpin^R^ extraction kit (Macherey-Nagel) and then sequenced. Sequence polymorphisms were determined by alignment.

Results {#Sec7}
=======

Mutations in *P. falciparum*DHFR and DHPS {#Sec8}
-----------------------------------------

The *dhfr* and *dhps* genes of *P. falciparum* were amplified and sequenced from randomly selected samples from all three island groups. The number of samples sequenced for these genes are detailed in Table  [1](#Tab1){ref-type="table"}. Sequencing analysis of *pfdhfr* revealed all isolates (n = 114) from all three island groups exhibited amino acid substitutions C59**R** and S108**N** having an allelic type AC**RN**I. Analysis of *pfdhps* revealed that 11/13, 16/17 and 23/26 samples were of wild type allele SAKAA, from Tanna Island, Vanuatu and Temotu and Malaita Provinces Solomon Islands, respectively. In addition one sample from Tanna Island, Vanuatu and three samples from Malaita Province, Solomon Islands possessed a single A437**G** substitution while one sample from Port Resolution on Tanna Island, Vanuatu was identified with a double substitution A437**G** + A581**G**. Furthermore, one sample from Utupua Island, Temotu Province, Solomon Islands carried a rare but widespread S436**F** mutation in conjunction with A437**G** and A613**S** substitutions resulting in a triple mutant allele **FG**KA**S** (Table  [1](#Tab1){ref-type="table"}).Table 1**Amino acid substitutions (bold) and prevalence in** ***P. falciparum*** **DHFR and DHPS from Vanuatu and Solomon Islands**PfDHFRAmino acid positionnFrequency165159108164Wild typeANCSIKnown substitutions in the region**VIRN/TL**CountryIsland/provinceVanuatuTanna Is.2222AC**RN**ISolomon IsTemotu Prov.3434AC**RN**IMalaita Prov.5858AC**RN**IPf DHPSAmino acid positionnFrequency436437540581613Wild typeSAKAAKnown substitutions in the region**A/FGEGS/T**CountryIsland/provinceVanuatuTanna Is.1311SAKAA1S**G**KAA1S**G**K**G**ASolomon IsTemotu Prov.1716SAKAA1**FG**KA**S**Malaita Prov.2623SAKAA3S**G**KAA

Mutations in *Plasmodium vivax*DHFR and DHPS {#Sec9}
--------------------------------------------

On Tanna Island, Vanuatu, 33/51 *P. vivax* isolates carried a double mutant *pvdhfr* allele with substitutions S58**R**/S117**N**. A further eleven isolates were triple mutant alleles P**M**ST**TF**, containing a novel F57**M** substitution, while the remaining seven isolates were double mutant alleles P**L**STS**F**. In Temotu Province, Solomon Islands there was a high incidence of samples containing mixed strains; these were excluded from further analysis. The dominant allele occurring in 32/40 samples was the *pvdhfr* quadruple mutant allele P**LRMT**I. Of the remaining isolates, four were single mutant alleles S117**N**, three were triple mutant alleles P**LR**T**T**I and one was a triple mutant allele P**LR**TS**M**. In contrast to *pvdhfr*, all *P. vivax* isolates (n = 108) analysed from all three regions possessed only a wild type *pvdhps* allele SAKAV in conjunction with one or more mutations in *pvdhfr* (Table  [2](#Tab2){ref-type="table"}).Table 2**Amino acid substitutions (bold) and prevalence in** ***P. vivax*** **DHFR and DHPS from Vanuatu and Solomon Islands**PvDHFRAmino acid positionnFrequency33575861117173Wild typePFSTSIKnown substitutions in the region**LI/LRNT/NL**CountryIsland/provinceVanuatuTanna Is.5133PF**R**T**N**I11P**M**ST**TF**7P**L**STS**F**Solomon IsTemotu Prov.4032P**LRMT**I4PFST**N**I3P**LR**T**T**I1P**LR**TS**M**Malaita Prov.4639P**LRMT**I3P**LR**TS**M**2PF**R** ~AGA~T**N**I1P**LR**T**N**I1PF**R** ~AGA~T**T**IPvDHPSAmino acid positionnFrequency382383512553585Wild typeSAKAVKnown substitutions in the region**GG**CountryIsland/provinceVanuatuTanna Is.3838SAKAVSolomon IsTemotu Prov.2222SAKAVMalaita Prov.4848SAKAV

Similarly, in Malaita Province, Solomon Islands, 39/46 isolates carried a *pvdhfr* quadruple mutant allele P**LRMT**I. A further three samples were triple mutant alleles P**LR**TS**M** carrying a novel I173**M** mutation, with another two samples identified as double mutant alleles PF**R**~AGA~T**N**I. The remaining allelic types consisted of single isolates P**LR**T**N**I and PF**R**~AGA~T**T**I. Interestingly, in Malaita Province, Solomon Islands, three samples possessed a S58**R** substitution where the arginine residue was coded by AGA, whereas in Temotu Province and Tanna Island, Vanuatu the arginine was solely coded by AGG (Table  [2](#Tab2){ref-type="table"}).

Discussion {#Sec10}
==========

Vanuatu and the Solomon Islands are among the few countries where ACT is used for treatment of both *P. falciparum* and *P. vivax* malaria. Understanding the parasite drug resistance profile at the time of ACT introduction allows for the detection of changes in future parasite populations. Although it is not clear whether parasites carrying mutant *dhfr* and *dhps* alleles have a selective advantage or disadvantage under AL pressure, the aim of this paper was to determine the base line polymorphisms of *pfdhfr, pfhdps, pvdfr and pvdhps* at the time of AL introduction in three island groups not previously surveyed.

Results of this study indicated that 100% of *P. falciparum* and *P. vivax* isolates from three island groups in Vanuatu and the Solomon Islands had point mutations in the gene coding for DHFR that are associated with antifolate resistance. In contrast, an average of 88.6% of *P. falciparum* isolates and 100% of *P. vivax* isolates possessed a wild type *dhps* gene. The differences in the prevalence of mutations between DHFR and DHPS supports the asymmetric selection pattern previously reported \[[@CR7]\] to occur in both species in these areas.

A double mutant *pfdhfr* allele, C59**R**/S108**N,** was detected in 100% of *P. falciparum* isolates tested from all three island groups. This pattern and fixation is similar to that reported for parasites collected on different islands to this study in the mid1990s and in 2005 \[[@CR13], [@CR16], [@CR17]\]. Based on earlier studies, point mutation S108**N** alone is sufficient to confer resistance to pyrimethamine \[[@CR5], [@CR23]--[@CR25]\], the addition of a C59**R** mutation in conjunction with S108**N** would result in a sizeable increase in the levels of resistance to pyrimethamine \[[@CR5], [@CR23]--[@CR25]\]. Although this double mutant allele does not confer SP resistance levels as high as the quadruple mutant alleles \[[@CR26]\], in some studies it has been implicated in treatment failures in young children \[[@CR27], [@CR28]\], while other studies indicate minimal SP treatment failures \[[@CR29], [@CR30]\]. The fixation of double mutant *pfdhfr* alleles in *P. falciparum* populations in Vanuatu and Solomon Islands indicates that children infected with *P. falciparum* could potentially experience treatment failure if SP usage was continued.

Previously published findings at different island locations in Vanuatu and Solomon Islands reported only wild type *pfdhps* alleles \[[@CR13], [@CR16], [@CR17]\]. In this study, although a majority of the *P. falciparum* isolates (50/56) from all three island groups had a wild type *pfdhps*, a small number of samples (6) possessed an A437**G** mutation. The *pfdhps* A437**G** mutation is often observed in regions where SP has been widely used and its presence alone, although more commonly when combined with mutation K540**E** and a triple DHFR mutation, is predictive of early SP treatment failure \[[@CR7], [@CR28], [@CR31]\]. In this study, no mutations were detected at amino acid position 540 of *pfdhps* in any of the samples investigated. This is not unexpected since earlier studies have indicated that the presence of K540**E** is often associated in the quintuple haplotype including three mutations in *pfdhfr* and two mutations in *pfdhps* \[[@CR31]\]. Interestingly, one sample from Port Resolution on Tanna Island, Vanuatu was identified as carrying a double mutant *pfdhps* allele A437**G** and A581**G**. This suggests that parasite populations were exposed to SP pressure since A581**G** is reported to increase in frequency with extended SP usage \[[@CR32]\]. It is also possible that this parasite isolate was imported from other areas because the village is located in a busy port serving inter-island sea travel.

The occurrence of double, triple and quadruple mutations in *pvdhfr* were observed in isolates from Tanna Island, Vanuatu as well as Temotu and Malaita Provinces, Solomon Islands. In Vanuatu the dominant allele occurring in 64% of isolates was the double mutant allele PNF**R**T**N**I, whereas in Malaita and Temotu Provinces, Solomon Islands, the dominant allele was the quadruple mutant allele PN**LRMT**I occurring in 85% and 80% of isolates, respectively. Amino acid codon 117 of *pvdhfr* has been reported to mutate to either an asparagine (N) or threonine (T). While S117**N** has been associated with reduced *in vitro* susceptibility to pyrimethamine it has not been reported to associate with the highly resistant quadruple mutant alleles, and has therefore been hypothesized as a "dead end" in resistance progression. In contrast, the S117**T** mutation has been associated with quadruple mutant alleles and clinical resistance to SP \[[@CR22], [@CR33]\]. On the other hand, the *pvdhfr* double mutants S58**R** + S117**N** are usually associated with delayed parasite clearance after SP treatment, not failure. This indicates that *P. vivax* isolates in Solomon Islands may have been under more extensive selection pressure than those in Tanna Island, Vanuatu. Mass drug administration of chloroquine and primaquine was one of the key preventive strategies used by the Malaria Eradication Programme in Solomon Islands from 1974 \[[@CR34]\] to the early 1990s.

Interestingly only wild type *pvdhps* alleles were detected in isolates from all three island groups. All *P. vivax* isolates had V585 that was previously reported to play a major role in the innate resistance of this parasite to sulphadoxine \[[@CR14]\].

Conclusion and implications {#Sec11}
===========================

This study provides baseline data on the extent of SP drug resistance in *P. vivax* and *P. falciparum* parasites in these three island groups prior to the introduction of ACT. In summary, 100% of *P. falciparum* parasites carried a double mutant *pfdhfr* allele with a small proportion of these also carrying a single or double *dhps* mutation. This indicates a moderate level of SP resistance in the *P. falciparum* populations that may cause SP treatment failure in young children. Similarly 100% of *P. vivax* isolates carried mutant *pvdhfr* alleles: a dominant double mutant allele in Vanuatu and a dominant quadruple mutant allele in Solomon Islands. It is speculated that *P. vivax* has developed a higher level of SP resistance in Solomon Islands compared to the sympatric *P. falciparum* population, and there is a higher level of SP resistance in *P. vivax* parasites from Solomon Islands than Vanuatu. This study demonstrates that the change of treatment policy from CQ + SP to ACT was timely.
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